Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study.

Abstract

BACKGROUND:

This prospective study assessed combined modality therapy of patients with International Union Against Cancer classification T1-4 N0 M0 anal cancer.

METHODS:

Protocol therapy consisted of a dose of 4000 cGy to the pelvis, anus, and perineum, followed by a 1000-1300 cGy boost. Infusions of 5-fluorouracil and mitomycin-C were administered when radiation therapy began. A second infusion of 5-fluorouracil was administered 28 days later. Biopsy was performed 6-8 weeks after completion of treatment. Positive biopsy findings resulted in abdominal-perineal resection.

RESULTS:

Survival at 7 years for 50 eligible patients was 58%. White patients and those with favorable performance status had significantly better survival. Of the 46 patients evaluable for response, 34 had a complete response, 11 had a partial response, and 1 had no response. Seven-year survival for partial responders was 53%. Freedom from locoregional progression was 80% at 7 years.

CONCLUSION:

Treatment with a combination of chemotherapy and radiation therapy is effective for patients with anal cancer. The investigation of methods of improving therapy is warranted.

• Authors: J A Martenson, S R Lipsitz, M Lefkopoulou, P F Engstrom, Y Y Dayal, C D Cobau, M M Oken, D G Haller
• Journal: Cancer (Cancer) Vol. 76 Issue 10 Pg. 1731-6 (Nov 15 1995) ISSN: 0008-543X [Print] United States
• PMID: 8625041 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Mitomycin
• Fluorouracil

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Anus Neoplasms (mortality, therapy)
• Combined Modality Therapy
• Female
• Fluorouracil (administration & dosage)
• Humans
• Male
• Middle Aged
• Mitomycin (administration & dosage)
• Prospective Studies
• Survival Rate